Less than a year after it was spun out of Spanish biotech firm Zeltia, Sylentis is hoping to become a major player in the RNAi drugs field with programs in ophthalmology and digestive disease.
The company, which currently has five full-time employees focused on research and development, is also in the process of establishing a scientific advisory board to help shepherd its lead drug compound — a treatment for glaucoma — through primate testing and into the clinic.